STAT Plus: ViiV takes steps to widen access to HIV prevention drug, but continues to encounter criticism
STAT+
STAT+ is STAT’s premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond. Learn more.
Latest
STAT Plus: Harris seeks to tie expanded Medicare drug price negotiation to home care, vision, hearing coverage expansion
STAT Plus: U.S. Supreme Court asks solicitor general for views on controversial Oklahoma law for regulating PBMs
STAT Plus: Pharmalittle: We’re reading about compounders suing the FDA, Biogen turning to telehealth, and more
STAT Plus: Compounding group sues FDA for removing Lilly’s obesity drug from its shortages list
STAT Plus: Biotech veteran John Maraganore raises $135 million for his ‘next-generation RNAi’ startup
STAT Plus: A pariah in science, the ‘CRISPR babies’ researcher gains support from a U.S. cryptocurrency entrepreneur
STAT Plus: Biogen turns to telehealth company to boost its postpartum depression drug
All Coverage
advertisement
